Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals.
Trinité B, Pradenas E, Marfil S, Rovirosa C, Urrea V, Tarrés-Freixas F, Ortiz R, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Lepore R, Izquierdo-Useros N, Trujillo G, Trapé J, González-Fernández C, Flor A, Pérez-Vidal R, Toledo R, Chamorro A, Paredes R, Blanco I, Grau E, Massanella M, Carrillo J, Clotet B, Blanco J. Trinité B, et al. Among authors: rovirosa c. Viruses. 2021 Jun 12;13(6):1135. doi: 10.3390/v13061135. Viruses. 2021. PMID: 34204754 Free PMC article.
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes.
Pradenas E, Trinité B, Urrea V, Marfil S, Ávila-Nieto C, Rodríguez de la Concepción ML, Tarrés-Freixas F, Pérez-Yanes S, Rovirosa C, Ainsua-Enrich E, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Valencia A, Izquierdo-Useros N, Paredes R, Mateu L, Chamorro A, Massanella M, Carrillo J, Clotet B, Blanco J. Pradenas E, et al. Among authors: rovirosa c. Med. 2021 Mar 12;2(3):313-320.e4. doi: 10.1016/j.medj.2021.01.005. Epub 2021 Jan 31. Med. 2021. PMID: 33554155 Free PMC article.
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.
Pradenas E, Trinité B, Urrea V, Marfil S, Tarrés-Freixas F, Ortiz R, Rovirosa C, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Valencia A, Izquierdo-Useros N, Noguera-Julian M, Carrillo J, Paredes R, Mateu L, Chamorro A, Toledo R, Massanella M, Clotet B, Blanco J. Pradenas E, et al. Among authors: rovirosa c. Cell Rep Med. 2022 Jan 24;3(2):100523. doi: 10.1016/j.xcrm.2022.100523. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35233547 Free PMC article.
Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
Trigueros M, Pradenas E, Palacín D, Muñoz-López F, Ávila-Nieto C, Trinité B, Bonet-Simó JM, Isnard M, Moreno N, Marfil S, Rovirosa C, Puig T, Grau E, Chamorro A, Martinez A, Toledo R, Font M, Ara J, Carrillo J, Mateu L, Blanco J, Clotet B, Prat N, Massanella M; CoronAVI@S and the KING cohort extension studies. Trigueros M, et al. Among authors: rovirosa c. Age Ageing. 2022 May 1;51(5):afac101. doi: 10.1093/ageing/afac101. Age Ageing. 2022. PMID: 35595256 Free PMC article.
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.
Abella E, Trigueros M, Pradenas E, Muñoz-Lopez F, Garcia-Pallarols F, Ben Azaiz Ben Lahsen R, Trinité B, Urrea V, Marfil S, Rovirosa C, Puig T, Grau E, Chamorro A, Toledo R, Font M, Palacín D, Lopez-Segui F, Carrillo J, Prat N, Mateu L, Clotet B, Blanco J, Massanella M; VAC-COV-GM-HMAR, KING Cohort Extension and CoronAVI@S studies. Abella E, et al. Among authors: rovirosa c. Life Sci Alliance. 2022 Aug 12;5(12):e202201479. doi: 10.26508/lsa.202201479. Life Sci Alliance. 2022. PMID: 35961779 Free PMC article.
The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis.
Pérez-Yanes S, Pernas M, Marfil S, Cabrera-Rodríguez R, Ortiz R, Urrea V, Rovirosa C, Estévez-Herrera J, Olivares I, Casado C, Lopez-Galindez C, Blanco J, Valenzuela-Fernández A. Pérez-Yanes S, et al. Among authors: rovirosa c. Front Microbiol. 2022 Mar 24;13:763039. doi: 10.3389/fmicb.2022.763039. eCollection 2022. Front Microbiol. 2022. PMID: 35401460 Free PMC article.
VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
Trinité B, Durr E, Pons-Grífols A, O'Donnell G, Aguilar-Gurrieri C, Rodriguez S, Urrea V, Tarrés F, Mane J, Ortiz R, Rovirosa C, Carrillo J, Clotet B, Zhang L, Blanco J. Trinité B, et al. Among authors: rovirosa c. Vaccine. 2024 May 31;42(15):3474-3485. doi: 10.1016/j.vaccine.2024.04.048. Epub 2024 Apr 18. Vaccine. 2024. PMID: 38641492 Free article.
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
Ávila-Nieto C, Vergara-Alert J, Amengual-Rigo P, Ainsua-Enrich E, Brustolin M, Rodríguez de la Concepción ML, Pedreño-Lopez N, Rodon J, Urrea V, Pradenas E, Marfil S, Ballana E, Riveira-Muñoz E, Pérez M, Roca N, Tarrés-Freixas F, Cantero G, Pons-Grífols A, Rovirosa C, Aguilar-Gurrieri C, Ortiz R, Barajas A, Trinité B, Lepore R, Muñoz-Basagoiti J, Perez-Zsolt D, Izquierdo-Useros N, Valencia A, Blanco J, Guallar V, Clotet B, Segalés J, Carrillo J. Ávila-Nieto C, et al. Among authors: rovirosa c. Nat Commun. 2024 Mar 21;15(1):2349. doi: 10.1038/s41467-024-46714-w. Nat Commun. 2024. PMID: 38514609 Free PMC article.
Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A, Amengual-Rigo P, Pons-Grífols A, Ortiz R, Gracia Carmona O, Urrea V, de la Iglesia N, Blanco-Heredia J, Anjos-Souza C, Varela I, Trinité B, Tarrés-Freixas F, Rovirosa C, Lepore R, Vázquez M, de Mattos-Arruda L, Valencia A, Clotet B, Aguilar-Gurrieri C, Guallar V, Carrillo J, Blanco J. Barajas A, et al. Among authors: rovirosa c. J Transl Med. 2024 Jan 3;22(1):14. doi: 10.1186/s12967-023-04843-8. J Transl Med. 2024. PMID: 38172991 Free PMC article.
Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.
Ávila-Nieto C, Vergara-Alert J, Amengual-Rigo P, Ainsua-Enrich E, Brustolin M, Rodríguez de la Concepción ML, Pedreño-Lopez N, Rodon J, Urrea V, Pradenas E, Marfil S, Ballana E, Riveira-Muñoz E, Pérez M, Roca N, Tarrés-Freixas F, Carabelli J, Cantero G, Pons-Grífols A, Rovirosa C, Aguilar-Gurrieri C, Ortiz R, Barajas A, Trinité B, Lepore R, Muñoz-Basagoiti J, Perez-Zsolt D, Izquierdo-Useros N, Valencia A, Blanco J, Clotet B, Guallar V, Segalés J, Carrillo J. Ávila-Nieto C, et al. Among authors: rovirosa c. Front Immunol. 2023 Dec 4;14:1291972. doi: 10.3389/fimmu.2023.1291972. eCollection 2023. Front Immunol. 2023. PMID: 38124756 Free PMC article.
14 results